Briani C, Zara G, Rondinone R, Della Libera S, Ermani M, Ruggero S, Ghirardello A, Zampieri S, Doria A
Department of Neurosciences, Rheumatology Division, University of Padova, Italy.
Neurology. 2004 Jun 22;62(12):2288-90. doi: 10.1212/01.wnl.0000130499.91775.2c.
The authors prospectively followed 14 patients treated with thalidomide for cutaneous lupus erythematosus (CLE), in order to evaluate the occurrence of peripheral neuropathy (PN) and to assess whether PN correlates with thalidomide dose. The patients were followed for up to 24 months with neurologic and electrophysiologic evaluations. Seven patients (50%) developed sensory axonal PN. The median time free from PN was 14 months. PN occurred after 10 months in the majority of patients. No correlations were found between thalidomide cumulative dose and occurrence of PN (Mann-Whitney U test; p > 0.16).
作者前瞻性地跟踪了14例接受沙利度胺治疗皮肤红斑狼疮（CLE）的患者，以评估周围神经病变（PN）的发生情况，并评估PN是否与沙利度胺剂量相关。对这些患者进行了长达24个月的神经学和电生理学评估。7例患者（50%）发生了感觉轴索性PN。无PN的中位时间为14个月。大多数患者在10个月后发生PN。未发现沙利度胺累积剂量与PN发生之间存在相关性（曼-惠特尼U检验；p>0.16）。
